Faculty profile

Eileen Rakovitch

ResearcherDepartment of Radiation OncologyUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Eileen Rakovitch

Researcher

Department of Radiation Oncology

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
25 publications in the last five years, latest in 2026.
Senior (last) author on 11 recent papers, a sign of leading a research group.
Principal investigator on 5 research grants (5 CIHR), most recently in 2022.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

1,660

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Breast Cancer Dcis Biomarkers Radiotherapy Ductal Carcinoma In Situ Progression Recurrence Low Risk

Latest papers

Appropriate Treatment for Stage 1 and 2 Her2-Positive and Triple-Negative Breast Cancer by Immigration Status in Ontario, Canada
Clinical Breast Cancer · 2026 · senior author
Mammographic screening and time to breast cancer diagnosis among immigrants and long-term residents in Ontario
BMC Cancer · 2026 · senior author
Long-term patient-reported outcomes in a randomized controlled trial of Mepitel Film versus standard of care for the prevention of acute breast radiation dermatitis
Breast Cancer Research and Treatment · 2026

All 89 publications

Latest funding

Simultaneous Integrated Boost (SIB) for Ultra-Hypofractionated (UH) Adjuvant Radiotherapy in High Risk Early Stage Breast Cancer
CIHR · 2026 · Co-investigator
$3,048,525
Simultaneous Integrated Boost (SIB) for Ultra-Hypofractionated (UH) Adjuvant Radiotherapy in High Risk Early Stage Breast Cancer
CIHR · 2025 · Co-investigator
$100,000
Validation of a novel biomarker classifier that predicts radiation response following breast-conserving surgery for ductal carcinoma in situ (DCIS)
CIHR · 2022 · Nominated PI
$1,981,352

All 12 grants and awards

89 publications.

Appropriate Treatment for Stage 1 and 2 Her2-Positive and Triple-Negative Breast Cancer by Immigration Status in Ontario, Canada

Fatiregun O, Sutradhar R, Podolsky S, Eisen A, Paszat L, Rakovitch E

Clinical Breast Cancer20264 citationsSenior author

DOI: 10.1016/j.clbc.2025.07.013

Mammographic screening and time to breast cancer diagnosis among immigrants and long-term residents in Ontario

Fatiregun OA, Sutradhar R, Podolsky S, Eisen A, Paszat L, Rakovitch E

BMC Cancer2026Senior author

DOI: 10.1186/s12885-026-15693-0

Long-term patient-reported outcomes in a randomized controlled trial of Mepitel Film versus standard of care for the prevention of acute breast radiation dermatitis

Bayrakdarian S, Hircock C, Wong HCY, Zhang L, Ding K, Karam I, Gallant F, Rakovitch E, Tran W, Soliman H

Breast Cancer Research and Treatment2026

DOI: 10.1007/s10549-026-07987-5

Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group.

Gunster JLB, Tramm T, Machiels M, Demaria S, Formenti SC, de Caluwe A, Duane F, Klein J, Sur D, Somaiah N, Rakovitch E, Jerzak KJ, Lu FI, Hiley CT, Brackstone M, Ehinger A, Maley SK, Acs B, Zerdes I, Ozcan D, Khramtsov A, Salido E, Papathomas TG, Sharma P, Stecklein S, Khramtsova G, Horvath Z, Markov D, Hardas A, do Prado Moura JF, Ramirez A, Woodward WA, Sivapiragasam A, Denkert C, Michiels S, Loi S, Poortmans P, Mutter RW, Salgado R, Tran WT, International Immuno-Oncology Biomarker Working Group

The Lancet. Oncology2026

DOI: 10.1016/s1470-2045(26)00255-x PMID: 42636842

External Beam Breast and Chest Wall Re-Irradiation Following Resection of Ipsilateral Breast Cancer Recurrence: Dose-Toxicity Relationships and Long-Term Oncologic Outcomes.

Ghosh S, Soliman H, Chow E, Chen H, Leung E, Karam I, Rakovitch E, Safavi AH, Vesprini D, Czarnota GJ

Cancers2026

DOI: 10.3390/cancers18172878 PMID: 42738398

A computer vision method to evaluate tumor-infiltrating lymphocytes and multiparametric modeling of neoadjuvant systemic therapy response in breast cancer.

Bielecki M, Lu FI, Vo A, Rakovitch E, Jerzak KJ, Salgado R, Karshafian R, Tran WT

Therapeutic advances in medical oncology2026

DOI: 10.1177/17588359261417762 PMID: 41732656

Impact of Immigration Status on Survival Among Stage 1 and 2 HER2‐Positive and Triple‐Negative Breast Cancer in Ontario, Canada

Fatiregun O, Sutradhar R, Podolsky S, Eisen A, Paszat L, Rakovitch E

Cancer Medicine20252 citationsSenior author

DOI: 10.1002/cam4.71288

Omission of anthracyclines from neoadjuvant chemotherapy for breast cancer: a population-based analysis

Mata DGMM, Sutradhar R, Castelo M, Hahn E, Nguyen L, Rodin D, Fatiregun O, Trebinjac S, Paszat L, Eisen A

Breast Cancer Research and Treatment20251 citationsSenior author

DOI: 10.1007/s10549-025-07778-4

Generative and integrative modeling for transcriptomics with formalin fixed paraffin embedded material.

Mucaki EJ, Zhang W, Saha A, Trebinjac S, Nofech-Mozes S, Rakovitch E, Dumeaux V, Hallett MT

Journal of translational medicine2025

DOI: 10.1186/s12967-025-07031-y PMID: 41029822

Mutational landscape of pure ductal carcinoma in situ and associations with disease prognosis and response to radiotherapy.

Rizvi N, Mucaki EJ, Salmini EL, Zhang M, Trebinjac S, Hahn E, Paszat L, Nofech-Mozes S, Hallett MT, Rakovitch E, Dumeaux V

Breast cancer research : BCR2025

DOI: 10.1186/s13058-025-02080-z PMID: 40629431

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2022

Subject: Prospective PhD student: Breast Cancer Dear Professor Rakovitch, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Appropriate Treatment for Stage 1 and 2 Her2-Positive and Triple-Negative Breast Cancer by Immigration Status in Ontario, Canada" (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Validation of a novel biomarker classifier that predicts radiation response following breast-conserving surgery for ductal carcinoma in situ (DCIS)" (2022), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Eileen Rakovitch

Research

Latest papers

Latest funding

Appropriate Treatment for Stage 1 and 2 Her2-Positive and Triple-Negative Breast Cancer by Immigration Status in Ontario, Canada

Mammographic screening and time to breast cancer diagnosis among immigrants and long-term residents in Ontario

Long-term patient-reported outcomes in a randomized controlled trial of Mepitel Film versus standard of care for the prevention of acute breast radiation dermatitis

Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group.

External Beam Breast and Chest Wall Re-Irradiation Following Resection of Ipsilateral Breast Cancer Recurrence: Dose-Toxicity Relationships and Long-Term Oncologic Outcomes.

A computer vision method to evaluate tumor-infiltrating lymphocytes and multiparametric modeling of neoadjuvant systemic therapy response in breast cancer.

Impact of Immigration Status on Survival Among Stage 1 and 2 HER2‐Positive and Triple‐Negative Breast Cancer in Ontario, Canada

Omission of anthracyclines from neoadjuvant chemotherapy for breast cancer: a population-based analysis

Generative and integrative modeling for transcriptomics with formalin fixed paraffin embedded material.

Mutational landscape of pure ductal carcinoma in situ and associations with disease prognosis and response to radiotherapy.

Frequent collaborators

Lawrence Paszat

Rinku Sutradhar

Sharon Nofech-Mozes

Danielle Rodin

Justin Lee

Timothy Whelan

Andrea Eisen

Mira Goldberg

Ewa Szumacher

Ali Sadeghi-Naini

William Tran

Janet Ellis

Sameer Parpia

Laurie Elit

Iwa Kong

Gregory Czarnota

James Wright

Muriel Brackstone

Allan Covens

Vanessa Dumeaux

Mark Ruschin

Maureen Trudeau

Elysia Donovan

Himu Lukka

Jonathan Sussman

Zuzana Kos

Michael Hallett

Breffni Hannon

Michael Brundage

Arjun Sahgal

Nicole Look Hong

Chris Bell

Eric Vigneault

Michael Yan

Lisa Di Prospero

Gregory Pond

Lee Chin

Harold Reiter

Betty Chui

Nicole Hodgson